

Supplemental Digital Content 1. Table: Description of comorbidities present in SARS-COV-2 positive children

Comorbid system	Specific Diagnoses	n (%)
Pulmonary disease (n=73)	Asthma	53 (73)
	Sleep apnea	29 (40)
	Chronic lung disease	10 (14)
Gastrointestinal disease (n=45)	Gastro/esophageal disorders	16 (36)
	Gastrostomy or jejunostomy dependence	14 (31)
	Chronic constipation or encopresis	10 (22)
Endocrine disease (n=23)	Diabetes or pre-diabetes	7 (30)
	Hyper/dyslipidemia or high cholesterol	5 (22)
	Adrenal insufficiency	4 (17)
Cardiac disease (n=15)	Congenital cardiac disease	6 (40)
	Hypertension	5 (33)
	Cardiomyopathy/heart failure	4 (27)
Neurologic disease (n=42)	Seizure disorder	19 (45)
	Structural brain defect/malformation	12 (29)
	Cerebral palsy	9 (21)
Psychiatric disease ^a (n=22)	Depression	15 (68)
	Anxiety	14 (64)
Developmental/behavioral (n=38)	Specific developmental delay	18 (47)
	Global developmental delay	14 (37)
	Autism spectrum disorder	9 (24)
Otolaryngologic disease (n=27)	Chronic or recurrent otitis media	8 (30)
	Hearing loss	6 (22)
	Chronic rhinosinusitis	4 (15)

^aThe top three diagnoses were included under each system. If only two diagnoses are listed, there were only two reported. Percentages may add up to greater than 100% due to some patients with multiple diagnoses

Supplemental Digital Content 2. Table: COVID-19 directed therapy among symptomatic admitted children

COVID-19 directed therapy	N (%)^a
Anti-viral therapy	8 (12)
remdesivir	6 (9)
hydroxychloroquine	3 (4.5)
Immunomodulatory therapy	10 (15)
convalescent plasma	4 (6)
anakinra	2 (3)
intravenous immunoglobulin	7 (11)
systemic corticosteroids ^b	3 (4.5)
infliximab	2 (3)

^aPercentage of symptomatic admitted patients who received a specific treatment regimen. Note some patients received multiple therapies.

^bExcludes patients who received corticosteroids for other reasons (ie. asthma exacerbation)